“The availability of the TAXUS system will positively impact patients’ lives, meaning they
will not have a recurrence of angina, they will not need to undergo repeat angiograms, angioplasties or cardiac surgery in the future. The TAXUS system truly will increase the quality of their lives and increase the general health of society as a whole.” 


Gregg W. Stone, M.D., TAXUS IV Clinical Trial Principal Investigator and Vice Chairman of The Cardiovascular Research Foundation at the Lenox Hill Heart and Vascular Institute, New York.
1 2 3